Funding Rounds
HepaRegeniX

HepaRegeniX Series C (2024, $16M)

HepaRegeniX

Developer of a regenerative therapy for the treatment of acute and chronic liver diseases.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series C

Raised Amount: $16.30M

Raised Date: 2024-10-01

Investors